Stryker Q4 net sales rise 11.4%, beat estimates

Overview

• Medical technologies firm's Q4 net sales rose 11.4%, beating analyst expectations

• Adjusted EPS for Q4 increased 11.5%, beating analyst expectations

• Company expects 2026 organic net sales growth of 8.0% to 9.5%

Outlook

• Company expects 2026 organic net sales growth between 8.0% and 9.5%

• Stryker forecasts 2026 adjusted EPS between $14.90 and $15.10

• Company anticipates slightly positive impact from foreign exchange on 2026 results

Result Drivers

• MEDSURG AND NEUROTECHNOLOGY GROWTH - Segment net sales increased 17.5% in Q4, driven by strong unit volume growth

• ORTHOPAEDICS SEGMENT - Organic net sales increased 8.4% in Q4, driven by unit volume growth

• OPERATING MARGIN IMPROVEMENT - Adjusted operating income margin increased 100 bps to 30.2% in Q4

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Stryker Corp is $432.50, about 20.9% above its January 28 closing price of $357.83

• The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago

Press Release: ID:nGNE9clt5n

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.